Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.80 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.77 |
| ▸ | GAK | O14976 | 3/20 | 0.77 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.77 |
| ▸ | BUB1 | O43683 | 2/20 | 0.77 |
| ▸ | STK10 | O94804 | 2/20 | 0.77 |
| ▸ | ABL1 | P00519 | 2/20 | 0.77 |
| ▸ | LCK | P06239 | 2/20 | 0.77 |
| ▸ | LYN | P07948 | 2/20 | 0.77 |
| ▸ | RET | P07949 | 2/20 | 0.77 |
| ▸ | SRC | P12931 | 2/20 | 0.77 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.77 |
| ▸ | FECH | P22830 | 2/20 | 0.77 |
| ▸ | KDR | P35968 | 2/20 | 0.77 |
| ▸ | FLT3 | P36888 | 2/20 | 0.77 |
| ▸ | MAP3K1 | Q13233 | 2/20 | 0.77 |
| ▸ | PLK4 | O00444 | 1/20 | 0.77 |
| ▸ | CIT | O14578 | 1/20 | 0.77 |
| ▸ | AURKA | O14965 | 1/20 | 0.77 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1507594 | 0.95 | EGFR (0.89) | EGFRERBB2GAKRIPK2BUB1 | |
| Hydrochloric Acid SCHEMBL1507714 | 0.94 | EGFR (0.87) | EGFRERBB2GAKRIPK2BUB1 | |
| Hydrochloric Acid SCHEMBL29607083 | 0.94 | EGFR (0.87) | EGFRERBB2GAKRIPK2BUB1 | |
| Erlotinib SCHEMBL27924332 | 0.91 | EGFR (0.88) | EGFRERBB2GAKRIPK2BUB1 | |
| SCHEMBL29577864 | 0.90 | EGFR (0.79) | EGFRERBB2GAKRIPK2BUB1 | |
| SCHEMBL4108602 | 0.90 | FBP1 (0.84) | EGFRERBB2GAKRIPK2BUB1 | |
| SCHEMBL1731532 | 0.90 | EGFR (0.87) | EGFRERBB2GAKRIPK2BUB1 | |
| Hydrochloric Acid SCHEMBL1507613 | 0.89 | EGFR (0.83) | EGFRERBB2GAKRIPK2BUB1 | |
| SCHEMBL1656960 | 0.89 | FBP1 (0.85) | EGFRERBB2GAKRIPK2BUB1 | |
| SCHEMBL1507409 | 0.89 | EGFR (1.00) | EGFRERBB2GAKRIPK2BUB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159529-A1 | AROMATIC COMPOUND AND APPLICATION THEREOF IN ANTITUMOR DRUG | SHANGHAI ZHEYE BIOTECHNOLOGY CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230143751-A1 | Aromatic Compound And Use Thereof In Preparing Antineoplastic Drugs | SHANGHAI ZHEYE BIOTECHNOLOGY CO. LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-9090633-B2 | Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITED (IN) | 2015-07-28 | — | — | US | disclosed |
| US-8815879-B2 | Substituted 4-(selenophen-2(or-3)-ylamino)pyrimidine compounds and methods of use thereof | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITED (US) | 2014-08-26 | — | — | US | disclosed |
| US-20130287767-A1 | SUBSTITUTED 4-(ARYLAMINO) SELENOPHENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITED (IN) | 2013-10-31 | — | — | US | disclosed |
| US-20130266563-A1 | SUBSTITUTED 4-(SELENOPHEN-2(OR-3)-YLAMINO)PYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITED (IN) | 2013-10-10 | — | — | US | disclosed |
| US-20130096100-A1 | DI(ARYLAMINO)ARYL COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-04-18 | — | — | US | disclosed |
| US-8318702-B2 | Di(arylamino)aryl compounds | ASTELLAS PHARMA INC. (JP) | 2012-11-27 | — | — | US | disclosed |
| US-20100099658-A1 | DI(ARYLAMINO)ARYL COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096100-A1 | DI(ARYLAMINO)ARYL COMPOUND | ERBB4, EGFR, ALK | EGFR 2/4885ERBB2 6/4885GAK 1183/4885 |
| US-20100099658-A1 | DI(ARYLAMINO)ARYL COMPOUND | ERBB4, EGFR, ALK | EGFR 2/4885ERBB2 6/4885GAK 1183/4885 |
| US-20230143751-A1 | Aromatic Compound And Use Thereof In Preparing Antineoplastic Drugs | TYR, MAPT, DDC | EGFR 1357/4885ERBB2 862/4885GAK 2103/4885 |
| US-20130266563-A1 | SUBSTITUTED 4-(SELENOPHEN-2(OR-3)-YLAMINO)PYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | RPS6, SULT1E1, SCLY | EGFR 319/4885ERBB2 258/4885GAK 2130/4885 |
| US-20130287767-A1 | SUBSTITUTED 4-(ARYLAMINO) SELENOPHENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | SELENOI, VHL, DPYD | EGFR 443/4885ERBB2 1100/4885GAK 740/4885 |
| US-20230159529-A1 | AROMATIC COMPOUND AND APPLICATION THEREOF IN ANTITUMOR DRUG | TYR, APC, TP53 | EGFR 1247/4885ERBB2 861/4885GAK 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.